Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

Author:

Imanishi Yasuo1ORCID,Ito Nobuaki2,Rhee Yumie3ORCID,Takeuchi Yasuhiro45,Shin Chan Soo6,Takahashi Yutaka7,Onuma Hiroki8,Kojima Masahiro8,Kanematsu Masanori8,Kanda Hironori8,Seino Yoshiki9,Fukumoto Seiji10

Affiliation:

1. Department of Metabolism, Endocrinology, and Molecular Medicine Osaka City University Graduate School of Medicine Osaka Japan

2. Division of Nephrology and Endocrinology The University of Tokyo Hospital Tokyo Japan

3. Department of Internal Medicine, Severance Hospital, Endocrine Research Institute Yonsei University College of Medicine Seoul Republic of Korea

4. Endocrine Center Toranomon Hospital Tokyo Japan

5. Okinaka Memorial Institute for Medical Research Tokyo Japan

6. Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea

7. Division of Diabetes and Endocrinology Kobe University Hospital Kobe Japan

8. Kyowa Kirin Co., Ltd. Tokyo Japan

9. Department of Pediatrics Osaka Hospital, Japan Community Healthcare Organization (JCHO) Osaka Japan

10. Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences Tokushima University Tokushima Japan

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3